Market outlook of the psoriatic arthritis market
Psoriatic arthritis is a chronic inflammatory disease that affects the distal joints in the body and may also affect the back and sacroiliac joints of the pelvis. The global market for psoriatic arthritis is expected to witness moderate growth during the forecast period and factors like the increase in penetration of biologic therapies are expected to augment the prospects for growth in this market. Additionally, the recent launch of products like Otezla and Stelara is also expected to boost market growth during the forecast period, resulting in its moderate CAGR of nearly 5% by 2019.
In this market research report, Technavio analysts estimate the Americas to account for more than 40% of the total market share by 2019. High market dominion of this region can be attributed to factors such as the increase in public awareness and the growing preference for biologic drugs.
Segmentation by mechanism of action and analysis of: TNF inhibitors, PDE4 inhibitors, & interleukin blockers
The TNF inhibitors aid in suppressing the inflammatory response in the patients body. These inhibitors are used to manage diseases like rheumatoid arthritis, psoriatic arthritis, psoriasis, inflammatory bowel disease, and seronegative spondyloarthropathies. Moreover, its ability to use a targeted mechanism to treat most of the inflammatory and autoimmune diseases is primarily responsible for its high market share of almost 80% by 2019.
The report offers an analysis of each of the following segments and discusses its impact on the overall market growth -
• TNF inhibitors
• PDE4 inhibitors
• Interleukin blockers
• Others
Segmentation by type of disease and analysis of: mild, moderate, & severe psoriatic arthritis
The mild psoriatic arthritis segment accounts for more than 60% of all the diagnosed cases and is the most common type of psoriatic arthritis in patients across the globe. This condition affects less than four joints in the body and is also known as oligoarticular arthritis.
The report offers an analysis of each of the following segments and discusses its impact on the overall market growth -
• Mild psoriatic arthritis
• Moderate psoriatic arthritis
• Severe psoriatic arthritis
Competitive landscape and key vendors: Abbvie, Amgen, Janssen Pharmaceuticals
This market is primarily dominated by large vendors due to their extensive product portfolios. The company that manufactures and markets a drug that can treat psoriatic arthritis, and also exhibit a high safety and efficacy profile, is expected to gain a competitive advantage over its rivals during the forecast period.
Leading vendors in this market are -
• Abbvie
• Amgen
• Janssen Pharmaceuticals
• Celgene
• UCB
Other prominent vendors analyzed in this market study are Alder Biopharmaceuticals, Biogen Idec, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, F. Hofffmann-La Roche, Kyowa Hakko Kirin, Merck, Novartis, Pfizer, Sandoz, Sun Pharmaceuticals, and Takeda Pharmaceutical.
Key questions answered in the report include
• What will the market size and the growth rate be in 2019?
• What are the key factors driving the psoriatic arthritis market?
• What are the key market trends impacting the growth of the psoriatic arthritis market?
• What are the challenges to market growth?
• Who are the key vendors in the psoriatic arthritis market?
• What are the market opportunities and threats faced by the vendors in the psoriatic arthritis market?
• Trending factors influencing the market shares of APAC, EMEA, and the Americas?
• What are the key outcomes of the five forces analysis of the psoriatic arthritis market?
Technavio also offers customization on reports based on specific client requirement.
Related reports
• Global Rheumatoid Arthritis Drugs Market 2014-2018
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Product profiles
PART 04: Market research methodology
Research methodology
Economic indicators
PART 05: Introduction
Key market highlights
PART 06: Disease overview
Understanding the disease
Types of psoriatic arthritis
Symptoms
Risk factors
Diagnosis
Disease management
Quality of life
Epidemiology
PART 07: Pipeline portfolio
PART 08: Novel mechanisms targeted by pipeline candidates
Small molecules
Biologics
PART 09: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 10: Market segmentation by MoA
TNF-alpha inhibitors
PDE4 inhibitors
IL blockers
Others
PART 11: Market segmentation by type of molecule
Biologics
Small molecules
PART 12: Market segmentation by severity of disease
PART 13: Market segmentation by route of administration
Oral
Parenteral
Topical
PART 14: Market segmentation by dosage form
Solid
Liquid
Semi-solid
PART 15: Geographical segmentation
Psoriatic arthritis market in Americas
Psoriatic arthritis market in EMEA
Psoriatic arthritis market in APAC
PART 16: Market drivers
Increase in public awareness
Unmet medical needs
Growing patient population
Change in lifestyle patterns
PART 17: Impact of drivers
PART 18: Market challenges
Increasing costs of biologics
Loss of patent exclusivity of branded therapies
Use of CAM by patients
Adverse effects of drugs
PART 19: Impact of drivers and challenges
PART 20: Market trends
Emergence of biosimilars
Popularity of off-label and traditional treatment options
Patient assistance programs in the US
Dominance of market by biologics
PART 21: Vendor landscape
Competitive scenario
Market share analysis 2014
Other prominent vendors
PART 22: Key vendor analysis
AbbVie
Amgen
Celgene
Janssen Pharmaceuticals
UCB
PART 23: Appendix
List of abbreviations
PART 24: Explore Technavio
Exhibit 01: Product offerings 7
Exhibit 02: Types of psoriatic arthritis
Exhibit 03: Signs and symptoms of psoriatic arthritis
Exhibit 04: Risk factors for psoriatic arthritis
Exhibit 05: Diagnostic test for psoriatic arthritis
Exhibit 06: Treatment options for psoriatic arthritis
Exhibit 07: Management of psoriatic arthritis
Exhibit 08: Pipeline molecules for psoriatic arthritis
Exhibit 09: Psoriatic arthritis clinical trial by phase
Exhibit 10: Psoriatic arthritis clinical trial by status
Exhibit 11: Novel targets of the pipeline candidates
Exhibit 12: Tofacitinib
Exhibit 13: Ixekizumab
Exhibit 14: Sekukinumab
Exhibit 15: Bimekizumab
Exhibit 16: Global psoriatic arthritis market 2014-2019 ($ millions)
Exhibit 17: Five forces analysis
Exhibit 18: Segmentation of global psoriatic arthritis market by MoA
Exhibit 19: Segmentation of global psoriatic arthritis market by MoA 2014
Exhibit 20: Segmentation of global psoriatic arthritis market by type of molecule
Exhibit 21: Segmentation of global psoriatic arthritis market by severity of disease
Exhibit 22: Segmentation of global psoriatic arthritis market by route of administration
Exhibit 23: Segmentation of global psoriatic arthritis market by dosage form
Exhibit 24: Global psoriatic arthritis market by geography 2014
Exhibit 25: Psoriatic arthritis market in Americas 2014-2019 ($ millions)
Exhibit 26: Psoriatic arthritis market in EMEA 2014-2019 ($ millions)
Exhibit 27: Psoriatic arthritis market in APAC 2014-2019 ($ millions)
Exhibit 28: Global psoriatic arthritis market by geography 2014-2019 ($ millions)
Exhibit 29: Drivers in global psoriatic arthritis market
Exhibit 30: Impact of drivers
Exhibit 31: Challenges in global psoriatic arthritis market
Exhibit 32: Average annual cost of HUMIRA, Enbrel, and Remicade 2014 ($)
Exhibit 33: Approvals and patent expiries of branded biologics
Exhibit 34: Impact of drivers and challenges
Exhibit 35: Trends in global psoriatic arthritis market
Exhibit 36: YoY sales comparison of top drugs 2010-2014 ($ millions)
Exhibit 37: YoY sales comparison of top drugs 2010-2014 (%)
Exhibit 38: YoY global sales of HUMIRA 2010-2014 ($ millions)
Exhibit 39: AbbVie: Key takeaways
Exhibit 40: YoY global sales of Remicade 2010-2014 ($ millions)
Exhibit 41: YoY global sales of Simponi 2012-2014 ($ millions)
Exhibit 42: Janssen Pharmaceuticals: Key takeaways
Exhibit 43: YoY sales of Enbrel in US and Canada 2010-2014 (($ millions)
Exhibit 44: YoY sales of Enbrel in US 2010-2014 ($ millions)
Exhibit 45: YoY sales of Enbrel in Canada 2010-2014 ($ millions)
Exhibit 46: YoY sales of Enbrel in Japan 2010-2014 ($ millions)
Exhibit 47: Comparison of YoY sales of Enbrel in US, Japan, and Canada 2010-2014 ($ millions)
Exhibit 48: Amgen: Key takeaways
Exhibit 49: UCB: Key takeaways
Exhibit 50: Celgene: Key takeaways
Exhibit 51: AbbVie: Product segmentation by revenue 2014
Exhibit 52: AbbVie: Geographical segmentation by revenue 2014
Exhibit 53: Amgen: Business segmentation by revenue 2014
Exhibit 54: Amgen: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 55: Amgen: Geographical segmentation by revenue 2014
Exhibit 56: Celgene: Product segmentation by revenue 2014
Exhibit 57: Celgene: Product segmentation by revenue 2013 and 2014 ($ millions)
Exhibit 58: Celgene: Geographical segmentation by revenue 2014
Exhibit 59: Janssen Pharmaceuticals: Key therapeutic areas
Exhibit 60: UCB: Product segmentation by revenue 2014
Exhibit 61: UCB: Product segmentation by revenue 2013 and 2014
Exhibit 62: UCB: Geographical segmentation by revenue 2014
Exhibit 63: Geographical segmentation by revenue 2013 and 2014
